Article
Effect of CYP3A5, CYP3A4, and ABCB1 genotypes as determinants of tacrolimus dose and clinical outcomes after heart transplantation.
Transplantation proceedings - 1 Nov 2012
Díaz-Molina B, Tavira B, Lambert J L, Bernardo M J, Alvarez V, Coto E
Abstract excerpt
BACKGROUND: Tacrolimus (Tac) is mainly metabolized by cytochrome P450 3A isoenzymes. In a cohort of heart transplant recipients, we investigated the effect of CYP3A5, CYP3A4, and ABCB1/MDR1 polymorphisms on Tac dose requirements and the risk of developing new-onset diabetes after transplantation (NODAT). METHODS: A total of 65 heart transplant recipients were genotyped for 3 single nucleotide polymorphisms (SNPs)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
